Literature DB >> 2833498

Inhibition of thrombin-induced platelet activation by leupeptin. Implications for the participation of calpain in the initiation of platelet activation.

L F Brass1, S J Shattil.   

Abstract

Inhibitors of calcium-dependent proteases (calpains) such as leupeptin and antipain have been shown to selectively inhibit platelet activation by thrombin. Based upon this observation, it has been proposed that calpains play a role in the initiation of platelet activation. In the present studies, we have examined the effect of leupeptin on the earliest known event in thrombin-induced platelet activation: the interaction between the agonist, its receptors, and the guanine nucleotide-binding proteins which stimulate phospholipase C (Gp) and inhibit adenylyl cyclase (Gi). We found that leupeptin inhibited thrombin's ability to stimulate phosphoinositide hydrolysis, suppress cAMP formation, and dissociate Gp and Gi into subunits. Leupeptin had no effect, however, on the same responses to other agonists or on thrombin binding to platelets. Although these observations might suggest, as others have concluded, that calpain is involved in the initiation of platelet activation by thrombin, we also found that: 1) substituting platelet membranes for intact platelets and decreasing the free Ca2+ concentration below the threshold required for calpain activation did not diminish the effects of leupeptin on phosphoinositide hydrolysis and cAMP formation, 2) washing the platelets after incubation with leupeptin reversed the effects of the inhibitor, 3) permeabilizing the platelets with saponin did not enhance the inhibitory effects of leupeptin, and 4) leupeptin inhibited the proteolysis of fibrinogen and the hydrolysis of S2238 by thrombin. Similar results in these assays were obtained with antipain. Therefore, our observations suggest that the inhibition of platelet activation by leupeptin is due to a direct interaction with thrombin and need not reflect a role for calpain in the initiation of platelet activation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833498

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Targeted gene inactivation reveals a functional role of calpain-1 in platelet spreading.

Authors:  S M Kuchay; A J Wieschhaus; M Marinkovic; I M Herman; A H Chishti
Journal:  J Thromb Haemost       Date:  2012-06       Impact factor: 5.824

2.  Leupeptin-based inhibitors do not improve the mdx phenotype.

Authors:  Joshua Selsby; Klara Pendrak; Monica Zadel; Zuozhen Tian; Jennifer Pham; Ted Carver; Pedro Acosta; Elisabeth Barton; H Lee Sweeney
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-09-15       Impact factor: 3.619

3.  Regulation of ATP-sensitive K+ channels in insulinoma cells: activation by somatostatin and protein kinase C and the role of cAMP.

Authors:  J R de Weille; H Schmid-Antomarchi; M Fosset; M Lazdunski
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Double knockouts reveal that protein tyrosine phosphatase 1B is a physiological target of calpain-1 in platelets.

Authors:  Shafi M Kuchay; Nayoung Kim; Elizabeth A Grunz; William P Fay; Athar H Chishti
Journal:  Mol Cell Biol       Date:  2007-06-18       Impact factor: 4.272

5.  Purification and characterization of GDP-L-Fuc: N-acetyl beta-D-glucosaminide alpha1-->6fucosyltransferase from human blood platelets.

Authors:  J Kamińska; M C Glick; J Kościelak
Journal:  Glycoconj J       Date:  1998-08       Impact factor: 2.916

6.  Calpain I activation is not correlated with aggregation in human platelets.

Authors:  J S Elce; L Sigmund; M J Fox
Journal:  Biochem J       Date:  1989-08-01       Impact factor: 3.857

7.  Thrombin alters the synthesis and processing of CYR61/CCN1 in human corneal stromal fibroblasts and myofibroblasts through multiple distinct mechanisms.

Authors:  Emily A Andreae; Debra J Warejcka; Sally S Twining
Journal:  Mol Vis       Date:  2020-07-29       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.